Julia Chivu ’24 A new drug has been developed to target the metabolism of cancer. Associate Professor Paul M. Bingham and Research Assistant Professor Zuzana Zachar from Stony Brook University developed a unique class of anticancer drugs–including the first-in-class and FDA-approved drug CPI-613. A first-in-class drug produces new treatment options or outcomes by exploring an unprecedented mechanism of action. CPI-613, also referred to as devimistat, … Continue reading Investigating the Metabolism of Cancer